We have been particularly impressed with Gilead for the past several years, between Hep C and COVID related wins, but we’ve been a little more cautious about the Abbott spinoff called AbbVie.
I expect to be more bullish on AbbVie in 2026, as it continues to show both its R&D savvy, and deal-doing expertise. Here’s the latest from Fierce, on each of them:
…AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug.
Zejing Biopharmaceutical unwrapped a $100 million upfront payment from AbbVie in return for the option to license alveltamig, also known as ZG006, outside of China. Zejing has been evaluating the DLL3-targeting trispecific T-cell binder in late-stage trials for “cellular lung cancer and other DLL3-expressing malignancies,” according to Zejing’s filing with the Shanghai stock exchange….
Under the Dec. 30 agreement, AbbVie will hand over another $60 million if it takes up its ex-China license option, while milestone payments tied to the alveltamig program could potentially reach $1.07 billion….
Now you know — off to the art museums here… out, into the sunshine. Grin — with my Oregon Ducks set to play Indiana in a week’s time. Woot!
नमस्ते
Powerline Lies... 